VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Saturday. The firm issued a sell rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Monday, March 31st.

VolitionRx Stock Down 6.1 %

VNRX opened at $0.50 on Friday. The firm has a 50-day moving average price of $0.58 and a 200-day moving average price of $0.63. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.02. The company has a market capitalization of $48.26 million, a price-to-earnings ratio of -1.39 and a beta of 1.15.

Insider Activity

In other news, CEO Cameron John Reynolds purchased 181,818 shares of VolitionRx stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the transaction, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC purchased a new position in shares of VolitionRx during the fourth quarter worth about $36,000. Lagoda Investment Management L.P. lifted its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Northern Trust Corp grew its stake in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Two Sigma Securities LLC bought a new position in shares of VolitionRx in the 4th quarter worth $29,000. Finally, Geode Capital Management LLC raised its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares in the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.